49 results about "Mouse Macrophage" patented technology

The preparation method comprises the following steps: selecting PLGA (poly (lactic-co-glycolic acid)) with biocompatibility and biodegradability as a carrier material, loading an immunopotentiator alpha-tocopherol on PLGA nano-particles, and preparing the nano-particle immunologic adjuvant by using a nano-precipitation method, so as to obtain the nano-particle immunologic adjuvant with an immune synergistic effect. By controlling the polymer concentration and the drug concentration in the preparation process, the average particle size of the drug-loaded nano-particles is 90-120nm, the monodispersion coefficient is less than 0.2, the particle size of the product is uniform and stable, the encapsulation efficiency reaches 80% or more, the content of alpha-tocopherol in the nano-particles is 1-30%, and the drug-loaded nano-particles have a sustained-release effect of one month or more. The PLGA nanoparticles loaded with alpha-tocopherol can promote proliferation of mouse macrophages and enhance secretion of cell inflammatory cytokines and expression of surface costimulatory molecules, have a synergistic enhancement effect of the PLGA nanoparticles and alpha-tocopherol, and can be used as an effective immunologic adjuvant.

The invention discloses a circadian rhythm-based cosmetic raw material in-vitro repair efficacy evaluation method, and belongs to the field of cosmetic evaluation, and the method comprises the following steps: S1, HDFA human dermal fibroblast culture, and RAW264.7 mouse macrophage culture; s2, determining the detection concentration of the cosmetic raw materials through cell viability detection; s3, inducing HDFA human dermal fibroblasts with blue light, and detecting the expression quantity of the clock gene BMAL1 and / or CLOCK; s4, after cell scratches of the HDFA human dermal fibroblasts are made, the HDFA human dermal fibroblasts are induced by blue light, and the healing area of the cell scratches is detected; s5, inducing the RAW264.7 mouse macrophage model by virtue of an induction drug lipopolysaccharide, and detecting the expression quantity of a clock gene Dbp and / or Rev-erbalpha; s6, processing and analyzing detection results of the steps S3 to S5, and scoring the detection results; and summarizing all detection index scores. Different cell model detection results are combined, the repairing function of the cosmetic raw materials is subjected to multi-dimensional evaluation, the evaluation accuracy is improved, and the evaluation process is rapid and efficient.

This invention relates to a novel substance with in vitro anti-inflammatory activity, its preparation method, and its application. The chemical name of maltol-3-1'-ethoxyhexane-1”,2”,3”,4”,5”,6”-hexaol-(4'-2”)-glucopyranoside is C. 21 H 34 O 13 Preparation method: 1. Extract *Trollius chinensis* with 70% ethanol (v / v); 2. Concentrate the extract until no alcohol odor remains and load it onto a D101 macroporous resin column; 3. Elute the fraction from the D101 macroporous resin with 30% ethanol, separate by silica gel column chromatography and gel column chromatography, and then obtain *Trollius chinensis* glycoside C using high-performance liquid chromatography. *Trollius chinensis* glycoside C is used to prepare anti-inflammatory drugs. The IC50 of *Trollius chinensis* glycoside C in this invention inhibits the release of pro-inflammatory factors TNF-α and IL-6 from LPS-stimulated mouse macrophages (RAW264.7). 50 The concentrations were 22.8 μmol / L and 31.0 μmol / L, respectively, indicating that it has good in vitro anti-inflammatory activity. This invention belongs to the field of research on effective components of natural drugs.

The invention belongs to the technical field of natural pharmaceutical chemistry, and discloses a flavonoid compound in lomatogonium radiatum as well as a preparation method and application thereof.The flavonoid compound is separated from lomatogonium radiatum of a gentiaceae lomatogonium plant, the medicinal material of lomatogonium radiatum is extracted and concentrated, and the flavonoid compound is obtained. And sequentially carrying out macroporous adsorption resin separation, gel column chromatography separation, medium-low pressure ODS column chromatography separation and semi-preparative high performance liquid chromatography separation. Pharmacological studies show that the compound provided by the invention can effectively inhibit the levels of COX2, IL-6 and TNF-alpha in mouse macrophages RAW246.7 caused by lipopolysaccharide (LPS), which indicates that the compound has obvious anti-inflammatory activity and can be used for preparing anti-inflammatory drugs.

The present invention discloses terpene compounds derived from polar fungi, their preparation methods and applications, and respectively provides a calamenane-type sesquiterpene compound eutyacorane and a pimarane-type diterpene compound libertellenone Z derived from polar fungi. The structures are shown in the following formulas I and II respectively: The experimental results show that the two compounds have a better inhibition rate on the release of NO in the LPS-induced inflammatory model of mouse macrophages RAW264.7, providing a new type of choice for anti-inflammatory drugs.

The invention provides a traditional Chinese medicine feed additive for improving animal immunity and a preparation method thereof, and relates to the technical field of traditional Chinese medicine feed additives. The traditional Chinese medicine feed additive is prepared from twelve traditional Chinese medicines including astragalus membranaceus, immature bitter orange, fructus forsythiae, black beans, semen cuscutae, radix paeoniae alba, rosemary, thyme, litsea cubeba, mangosteen peel, cinnamon and origanum vulgare. The traditional Chinese medicine feed additive disclosed by the invention can be used for improving the immune organ index of an immunosuppressed mouse induced by cyclophosphamide, regulating the level of immune protein and inflammation-related factors and enhancing the phagocytic ability of macrophages of the mouse; the antibody titer of the Newcastle disease virus can be improved, the immune organ index of the chicken can be improved, and the secretion of IL-4, TNF-alpha and IFN-gamma in the chicken body can be promoted; mouse and broiler chicken tests show that the traditional Chinese medicine feed additive disclosed by the invention can improve the immune response capability of animals and enhance the immunity of the animals, and has a good application prospect in animal breeding.

The invention discloses ginseng polysaccharide GP40030-1 as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The ginseng polysaccharide GP40030-1 provided by the invention can obviously promote the proliferation of mouse macrophages RAW264.7 and effectively improve the phagocytic ability of cells, is dose-dependent in a concentration range of 12.5-100 mu g / mL, shows excellent immunomodulatory activity, and has a wide application prospect in the aspect of preparing medicines, functional foods or health products for enhancing immunity.

This invention discloses a series of 1-oxo-2,8-diazacyclic decanone derivatives, their synthesis methods, and applications, belonging to the field of pharmaceutical technology. The applicant's experimental results show that the derivatives of this invention have a good inhibitory effect on the release of NO from lipopolysaccharide-induced mouse RAW 264.7 macrophages, exhibiting good anti-inflammatory activity, and can be used to prepare drugs for treating inflammation.

The invention relates to a C2-quaternary carbon indole-3-ketone compound as well as a preparation method and application thereof, the structure of the compound is shown as a structural general formula (I-1) or (I-2), and the compound is prepared by taking an indole-3-ketone derivative or a 3, 3-gem-difluoroindole derivative as a reaction substrate and carrying out Mannich reaction. According to the present invention, the reaction conditions are mild, the atom economy is high, the highest yield of the synthesized C2-quaternary carbon indole-3-one compound can achieve 86%, and the prepared C2-quaternary carbon indole-3-one compound can inhibit NO released by LPS-induced mouse macrophages RAW264.7, and can be used for preparing drugs for treating NO-mediated inflammatory diseases. Or a product thereof

The invention discloses a CD47 antibody and application thereof. The CD47 monoclonal antibody 47-F provided by the invention has relatively strong affinity with human CD47 protein, and the Kd value reaches 0.4068 * 10 <-9 > M; the antibody is a mouse IgG1 subtype, and a light chain is a kappa chain; the antibody B6H12.2 can compete with the commodity CD47 antibody B6H12.2 to bind to target cells; mouse macrophages can be obviously induced to phagocytize B lymphoma cells Raji in vitro; the kit not only can be used for detecting the expression of human CD47 protein, but also can be applied to immunotherapy independently or in combination with other methods, and has diagnosis and treatment values in tumors, autoimmune diseases and inflammatory diseases.

The invention discloses a mussel immune active peptide and application thereof, and belongs to the technical field of active peptides, the sequence of the immune active peptide is FPR, FRE, KFP, LLPK or PDRM, and the acquisition of the immune active peptide is derived from digestion of mussel meat under a static simulation digestion model, polypeptide sequence identification, bioinformatics tool prediction, molecular docking and polypeptide synthesis and verification. The mussel immune active peptide disclosed by the invention has relatively good proliferation promoting activity and neutral red phagocytic ability of mouse macrophages RAW264.7. The screened mussel immune active peptide can be used as an auxiliary immune regulation active component to be applied to products with an immune function improving function, such as an immunomodulator, a pharmaceutical composition or a nutritional product, and has important guiding significance for development of new products.

The present invention contemplates new members of the diprovocim family of compounds that exhibit improvements in both potency and efficacy in the murine system, permitting more effective use in vivo in animal models while maintaining the remarkable activity agonist towards human TLR1 / TLR2. The prototypical new agonist called diprovocim-X exhibits the same excellent potency and efficacy of diprovocim-1 in human THP-1 cells (EC50 of 140 pM vs 110 pM with efficacy 100% that of diprovocim-1 and Pam3CSK4), and displays a superb EC50 of 750 pM in mouse macrophages with an efficacy 550% that of diprovocim-1. Diprovocim-X served as an adjuvant in vivo in mice when co-administrated with a non-immunogenic antigen (OVA), indicating stimulation of the adaptive immune response. These the new diprovocim family compounds are now functionalized for linkage to antigenic, targeting, or delivery moieties, properties to enable precision activation of coordinated innate and adaptive immune responses in target tissues.

The application belongs to the technical field of biology, and discloses a preparation method of a Salmonella typhimurium flagellin and Senecavirus antigen fusion protein. The application selects Escherichia coli Rosetta (DE3) as a host, fuses a Salmonella typhimurium flagellin gene and a Senecavirus antigen gene, optimizes codons, and then clones the fusion protein into a pET-28a (+) vector, so that the obtained fusion protein can keep the adjuvant activity of the flagellin, improve the solubility and expression level of VP2, and the yield can reach 40 mg / L, thereby greatly reducing the expression and purification process cost. The fusion protein provided by the application can activate the TLR5 path and activate mouse macrophages, and the production process is simple and low in cost, so that the application has important significance for the research and production of Senecavirus subunit vaccines.

The invention discloses 1, 4, 11-trioxo-10, 14-diazaspiro decanone as well as a synthesis method and application thereof, and belongs to the technical field of medicines. The test result of the applicant shows that the compound has a good inhibiting effect on NO released by lipopolysaccharide-induced mouse macrophage RAW 264.7, shows good anti-inflammatory activity and can be used for preparing the medicine for treating inflammation.

The invention discloses application of nintedanib in preparation of a medicine for treating plant migration and plant mineralization, and belongs to the technical field of biological medicine. The research shows that the nintedanib has the effects of reducing deposition of extracellular matrix of an allogeneic kidney transplantation model mouse, improving renal tubular atrophy, relieving mouse CD206 + macrophage infiltration and reducing rejection injury degree and immune infiltration degree of kidney grafts after being administered under the administration dosage without generating liver and kidney toxicity and intestinal side effects; the lesion process of mouse chronic transplanted kidney rejection is obviously slowed down, and the damage of excessively activated inflammatory cells to the transplanted kidney is reduced. The results show that nintedanib can delay the progress of chronic transplantation renal fibrosis.

The invention relates to a preparation method and application of M1 type macrophages, and the method comprises the following steps: adding activated mouse lymphocytes into a mouse macrophage culture system for co-culture to obtain the M1 type macrophages. The invention explores the identification of CD3 / CD28 activated lymphocytes, the influence of the activated lymphocytes on the morphology of macrophages and the influence of the activated lymphocytes on macrophage subtypes, and provides a brand-new method for obtaining the mouse M1 type macrophages. According to the invention, the problem that the polarization of the macrophage cannot be completely induced by singly using the recombinant IFN-gamma to stimulate the macrophage is solved. The invention provides a novel in-vitro mouse M1 type macrophage model for experimental research, M1 type macrophages induced by activated lymphocytes can better simulate an in-vivo immunoreaction process, a required cell state is obtained by utilizing co-culture of two cells in vivo, and compared with dependence on exogenous addition of viruses or compounds, the in-vitro mouse M1 type macrophage model provided by the invention has the advantages that the in-vitro immunoreaction process can be better simulated by the M1 type macrophages induced by the activated lymphocytes; according to the invention, many potential risks and bad places can be effectively avoided.

The present invention relates to styraxol derivatives having the structures of Formula (I), Formula (II), or Formula (III), or pharmaceutically acceptable salts thereof. These compounds have excellent anti-inflammatory activity and significantly inhibit the release of nitric oxide (NO), an inflammatory molecule, from mouse macrophages RAW264.7. #imgabs0#

The invention discloses a new application of isopentadecanoic acid, and discloses an application of isopentadecanoic acid in preparation of skin care cosmetics, isopentadecanoic acid has the effects of up-regulating expression of hBD-2 and silk protein in human immortalized keratinocytes, reducing expression synthesis of ROS and TRPV1 in the human immortalized keratinocytes, inhibiting release of NO by mouse macrophages, and inhibiting expression of the human immortalized keratinocytes. And the secretion of sebaceous gland cell grease is reduced.

The invention relates to the technical field of medicinal compounds, and particularly discloses a novel compound (S, E)-5-hydroxy-N-isobutyl-4-oxo-2-decenamide extracted and separated from anacyclus pyrethrum roots, and application of the novel compound in preparation of anti-inflammatory drugs. Modern spectrum technologies such as 1D-NMR (1D-Nuclear Magnetic Resonance), 2D-NMR (2D-Nuclear Magnetic Resonance), high-resolution mass spectrum and the like are used for carrying out structure identification on a monomeric compound obtained through separation, and the molecular structure of the compound is deduced. An enzyme activity experiment result shows that the novel compound has relatively good activity of inhibiting TYK2. Molecular docking results show that the novel compound and the target protein have good binding activity, and the interaction force is mainly hydrogen bonds and hydrophobic force. By detecting the inhibiting effect of the novel compound on the NO release amount of a mouse macrophage line RAW264.7, the novel compound has a good anti-inflammatory effect and has a good application prospect in the aspect of treating inflammation.

The invention discloses application of scylla serrata dodecapeptide in preparation of a skin relieving composition. The amino acid sequence of the scylla serrata dodecapeptide is as shown in SEQ ID NO.01. The invention further discloses a preparation method of the scylla serrata dodecapeptide. The blue crab dodecapeptide can effectively inhibit polarization of LPS-induced mouse macrophages RAW 264.7 to type 1 macrophages, secretion of proinflammatory factors and increase secretion of anti-inflammatory factors, can effectively relieve irritation of SDS to zebra fish embryos, does not show cytotoxicity to the mouse macrophages RAW 264.7, does not have an obvious stimulation effect on the zebra fish embryos, and can be used for preparing the anti-inflammatory and anti-inflammatory drugs. The traditional Chinese medicine composition has the effect of relieving inflammation and is relatively good in safety.

The present invention relates to the technical field of pharmaceutical compounds, and specifically discloses a new compound 11 extracted and separated from Tian Ping grass β ,13-(6-amino-purine-9-yl)-dihydrolactate, and the use of the new compound in the preparation of anti-inflammatory drugs. The present invention uses modern spectral techniques such as 1D-NMR, 2D-NMR, high-resolution mass spectrometry, etc. to structurally identify the separated monomer compounds and deduce the molecular structure of the compound. The results of enzyme activity experiments show that the new compound has good inhibitory activity against BTK. The results of molecular docking show that the new compound has good binding activity with the target protein, and the interaction force is mainly hydrogen bonding and hydrophobic forces. By detecting the inhibitory effect of the new compound on the NO release of the mouse macrophage cell line RAW264.7, it is shown that the new compound has good anti-inflammatory effect and has good application prospects in the treatment of inflammation.

A compound extracted from Amomum villosum and its preparation method and application belong to the field of Chinese medicine extraction, specifically to a compound of podocarpane type diterpenes or hemicarpane type diterpenes or kavalactones as shown in formula (I)-(IV) and its extraction method, wherein the compound has the effect of inhibiting the release of NO activity of mouse macrophages RAW264.7 induced by lipopolysaccharide (LPS) and protecting the oxidative damage of mouse neuromicroglioma cells BV-2 induced by hydrogen peroxide (H2O2), and can be used to prepare anti-inflammatory and antioxidant drugs. The present invention further enriches the structural diversity of the active substances of Amomum villosum, and on this basis, lays the foundation for the subsequent monomer compounds to carry out relevant biological activity tests, provides active lead compounds for new drug development, and also provides a theoretical basis for the in-depth research and development of Amomum villosum medicinal materials.

The present invention belongs to the field of preparation of longan ginseng peptide probiotic powder, and particularly relates to a traditional Chinese medicine fermented longan ginseng peptide probiotic powder for treating tumors. Ginseng and American ginseng are crushed and powdered, vacuum concentrated to make ginseng peptide concentrate, and mixed with dried longan, artemisia annua, ashwagandha, knotweed, tripterygium wilfordii, cordyceps sinensis, and composite probiotic agents in a fermenter for full fermentation. The effective ingredient content is high and is conducive to absorption, while clearing away heat and promoting body fluid without toxic side effects; finally, the traditional Chinese medicine fermented longan ginseng peptide probiotic powder prepared by vacuum freeze drying has minimal biological activity damage, completely retains the active ingredients for treating tumors, and is convenient for long-term storage. After liver cancer mice take it, the tumor weight and volume are effectively suppressed, the liver function is less damaged, and the immune function of mice is protected, and the macrophage phagocytosis rate of mice reaches 79.6%.

The invention relates to the technical field of biology, in particular to isoconic acid and analogues thereof, a preparation method of the isoconic acid and the analogues thereof and application of the isoconic acid and the analogues in diagnosis and treatment of inflammation-related diseases. The invention finds that isoconic acid as an inflammation biomarker and a novel metabolite with an anti-inflammatory effect has a relatively strong inhibition effect on M1 polarization of human and mouse macrophages induced by lipopolysaccharide (LPS); the LPS-induced mouse inflammation model has the effects of prolonging the survival time and relieving inflammation phenotypes of tissues such as brain, spleen and liver; the anti-inflammatory effects of expression, secretion and the like of inflammatory factors are reduced. The composition has the effects of reducing adipose tissue inflammatory factors and relieving weight gain in a high-fat diet inflammation model; in a mouse inflammatory bowel disease model, the compound has the effects of increasing the length and reducing steel research pathological scores and inflammatory factors. Therefore, the isoconic acid can be used for diagnosing and treating inflammatory diseases, such as septicopyemia, inflammatory bowel disease, neuroinflammation, inflammation caused by high fat diet and the like.

The present invention discloses an anti - enzymolysis antibacterial peptide FRL, its preparation method and application, belonging to the field of bioengineering. The sequence of the antibacterial peptide FRL is shown as SEQ ID No.1. This antibacterial peptide FRL exhibits narrow - spectrum antibacterial activity, can effectively inhibit Gram - negative bacteria, and has the potential to be applied in drugs for treating Gram - negative bacterial infectious diseases. This antibacterial peptide has very low hemolytic activity and eukaryotic cell toxicity. This antibacterial peptide fails to cause 10% erythrocyte hemolysis at a concentration of 128 μmol / L, and the survival rate of mouse macrophage RAW264.7 reaches more than 80%. This antibacterial peptide shows good stability against trypsin, pepsin, chymotrypsin, and proteinase K (0.4 mg / mL; 0.5 h) at pH = 5 and 37°C. In summary, the antibacterial peptide FRL has the development potential to become an alternative to antibiotics.

The invention discloses a synthetic method and application of antrodia camphorata galactomannan oligosaccharide and polysaccharide, and belongs to the field of carbohydrate chemistry and medicinal chemistry. According to the method, five tetrasaccharide building blocks are used as synthons, the construction efficiency of antrodia camphorata galactose 1, 2-cis-glucosidic bonds is improved through remote participation of galactose 4-position benzoyl, and octasaccharide, hexadecanose and tetracosanose of antrodia camphorata are stereoselectively constructed through [4 + 4], [8 + 8] and [16 + 8] glycosylation strategies by utilizing the method; the obtained oligosaccharides and polysaccharides are subjected to deprotection to obtain six antrodia camphorata galactomannan oligosaccharides and polysaccharides with definite structures, single components and anti-inflammatory activity. A cellular immune experiment shows that the oligosaccharide and the polysaccharide can inhibit LPS (lipopolysaccharide)-induced mouse macrophage RAW 264.7 inflammatory response, and have potential application in anti-inflammatory drugs; meanwhile, the antigens are good antigens of antrodia camphorata sugar vaccines and can be developed into sugar vaccines or sugar drugs.

The present invention discloses a CD47 antibody and its applications. The CD47 monoclonal antibody 47-F provided by the present invention has a strong affinity for human CD47 protein, with a Kd value of 0.4068×10-9 M; it is of murine IgG1 subtype and the light chain is κ chain; it can compete with the commercial CD47 antibody B6H12.2 for binding to target cells; it can significantly induce murine macrophages to phagocytize B lymphoma cell Raji in vitro; it can be used to detect the expression of human CD47 protein, and can also be used alone or in combination with other methods for immunotherapy, having diagnostic and therapeutic values in tumors, autoimmune diseases, and inflammatory diseases.

The present invention discloses a phenolic glycoside compound, a new chemical component discovered in the leaves of Illicium verum. The present invention also structurally identified the compound isolated by the above method through physicochemical properties and modern spectroscopic methods. The present invention also evaluated the activity of the compound using an LPS-induced RAW 264.7 cell inflammation model and other activity screening systems. The compound was found to have a certain protective effect on the mouse macrophage cell line RAW 264.7, significantly inhibiting the release of PGE2, demonstrating a strong anti-inflammatory effect.

The application discloses a series of hexa-parallel hexa benzofuran derivatives, a synthesis method and application thereof, and belongs to the technical field of medicines. Test results of the applicant show that part of the target compounds have good inhibitory effect on the release of NO in lipopolysaccharide-induced mouse macrophage RAW 264.7, and can be used for preparing medicines for treating inflammation.

The present invention provides a class of chain polyene vicinal diol compounds and their preparation methods and uses. The inventors obtained compounds Aspertrienediols A and B by separating and purifying the liquid fermentation extract of Antarctic Aspergillus sp.SCSIO 05702. Structural analysis showed that compounds 1 and 2 were both new compounds, and their specific structures were shown in formula (I). Through the evaluation of the anti-inflammatory activity of compounds 1 and 2, it was found that the new compound Aspertrienediol B (2) had a significant inhibitory effect on nitric oxide produced by mouse macrophage cell line RAW264.7 induced by lipopolysaccharide (LPS), and simultaneously inhibited the mRNA expression of pro-inflammatory factors such as MCP-1, IL-6 and TNF-α. At the same concentration, it had no cytotoxic activity on RAW264.7 cells, and could be used as a lead compound for the development of anti-inflammatory drugs.